Cryoablation followed by immune-checkpoint inhibitor treatment for III/IV lung cancer or metastatic lung cancer where standard treatment is ineffective

Cryoablation followed by immune-checkpoint inhibitor treatment for III/IV lung cancer or metastatic lung cancer where standard treatment is ineffective - Cryoablation followed by immune-checkpoint inhibitor treatment for lung cancer

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000038178

Enrollment

100

Registered

2019-10-04

Start date

2019-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

III or IV stage lung cancer or metastatic cancer where standard therapy is ineffective

Interventions

For Stage III/IV lung cancer or multiple metastatic lung cancer, the main tumor is treated by cryoablation, followed by statring immune-checkpoint inhibitor around 4 weeks later. After 4 cycles at min

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. III/IV stage lung cancer or multiple emtastatic lung cancer. 2. For metastatic lung cancer other than primary lung cancer, the tumors show microsatelite instability(MSI)-high. 3. Even having another metastatic tumors, the life extension is expected if the main tumor is treated by cryoablation. 4. Informed consent with risk and long-term forecast.

Exclusion criteria

Exclusion criteria: 1. Patients having obvious interstitial pneumia. 2. Tumors located where the cryoprobe insertion is not available.

Design outcomes

Primary

Measure	Time frame
For patients with III/IV stage lung cancer or multiple metastatic lung cancer who are refractory to standard therapy, the main lung tumor is treated by cryoablation followed by starting immune checkpoint inhibitor around 4 weeks later with 4 cycles at minimum. The efficacy of the drug is investigated especially whether it is superior over the effective rate reported so far.	—

Secondary

Measure	Time frame
To investigate whether the cryoablation for lung cancer increase the interstitial pneumonia, which is one of side effects of immune checkpoint inhibitor.	—

Countries

Japan

Contacts

Public ContactHiroaki Nomori

Kashiwa Kousei General Hospital Thoracic Surgery

hnomori@qk9.so-net.ne.jp0471-45-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026